CLEVELAND, June 7, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Shin-Matsudo Central General Hospital has purchased a MRIdian MRI-guided radiation therapy system for installation at Shin-Matsudo Accuracy Radiation Therapy (SMART) Center in Japan. This is the third MRIdian system in Japan intended to help address an unmet need with a growing population and an increasing rate of cancer patients in Toukatsu. The center expects to begin patient treatments in the early Fall of 2023.

With a population of three million in the Toukatsu area, there is a potential shortage of radiation treatment facilities. The addition of a MRIdian system is intended to help address this issue by providing cutting-edge radiation to local patients. The hospital intends to utilize MRIdian's full capabilities including stereotactic body radiation therapy (SBRT) and hypofractionated radiation delivery, as well as on-table adaptive therapy, for various indications with an emphasis on those that require extreme precision such as pancreas, prostate, lung, and oligometastatic disease.

"I believe that introduction of cutting-edge radiation therapy systems such as MRIdian to our hospital will bring a great deal of value to the local patients. MRIdian's ability to track tissue real time with automated beam gating will offer the precision necessary to treat a growing number of patients. As the director of the hospital, I am very much proud that our medical team, centered on Dr. Jun Itami, can offer the best medical care to the society," said Dr. Ryota Matsuo, Hospital Director, Shin-Matsudo Central General Hospital.
"The crisis of a growing population of cancer patients cannot be solved without expanding access to innovative technologies that increase treatment options for patients who need personalized cancer therapy for a variety of hard-to-target cancers," said Paul Ziegler, Chief Commercial Officer of ViewRay. "This expansion in Japan reduces barriers by increasing access and further builds equity within their healthcare system."

The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.

To date, over 22,000 patients have been treated with MRIdian. Currently, 51 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations.


About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.


SOURCE ViewRay, Inc.

MRI Homepage